Evicenter
P&T meetings

Tinlarebant (LBS-008)

Stargardt disease type 1

Manufacturer
Belite Bio
Regulatory submission
NDA submitted June 2026
Last updated
66 sources

Product information and disease descriptionPlace of product in therapyDisease descriptionBurden of Stargardt disease type 1

Humanistic burden and health-related quality of life

4 evidence topics · 6 sources

Vision-specific quality of life and functional vision: Brazil

“41 patients with STGD and 46 healthy volunteers” (opens the source at this quote in a new tab)

“Individuals with STGD had significant impairment of vision-specific QoL and functional vision compared with controls” (opens the source at this quote in a new tab)

Mental health outcomes in inherited retinal diseases: Stargardt disease subgroup

“only two studies encompassing 75 participants” (opens the source at this quote in a new tab)

Patient-reported outcome measures in recessive Stargardt disease

“Properties of Patient-Reported Outcome Measures in Recessive Stargardt Disease” (opens the source at this quote in a new tab)

“The NEI VFQ and IVI have acceptable psychometric properties in STGD1” (opens the source at this quote in a new tab)

Daily functioning, independence, and caregivers: daily functioning

“lose the ability to read, drive, and recognize faces, leading to difficulty in school, work, social situations, and loss of independence.” (opens the source at this quote in a new tab)